Loading organizations...
§ Private Profile · Auckland, New Zealand
Medtech startup developing medical devices for reconstructive microsurgery, offering microvascular implants to connect micro-arteries and veins faster.
Founded in 2018 by Nandoun Abeysekera, Avasa is an Auckland, New Zealand based medical technology startup developing microvascular implants for reconstructive microsurgery. Its lead product is the Avasa Coupler, an implantable device enabling surgeons to connect microarteries and veins eighty percent faster than traditional hand sewing while improving safety and surgical standardization. Nearing market entry and clearance from the Food and Drug Administration, this device recently reached its design freeze and achieved a perfect success rate during chronic animal studies. Operating with fewer than 25 employees, the venture funded enterprise recently secured an oversubscribed Pre-Series A funding round of 4.75 million NZD led by Movac, building upon 2.65 million dollars in prior financing. Before this investment, the medtech firm joined a deep tech incubator operated by Bridgewest Ventures and received grant support from Callaghan Innovation.
Avasa has raised $4.5M across 2 funding rounds.
Avasa has raised $4.5M in total across 2 funding rounds.
Avasa has raised $4.5M across 2 funding rounds. Most recently, it raised $3.0M Seed in August 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2025 | $3M Seed | Byron VAN Vugt | NZ Growth Capital Partners Aspire Fund, Saum Vahdat | Announced |
| Sep 14, 2023 | $1.6M Venture Round | — | Booster Innovation Fund, Bridgewest Group, Brisbane Angels, Cure Kids Ventures, Jacques Richter, Pacific Channel, Uniservices | Announced |
Avasa has raised $4.5M in total across 2 funding rounds.
Avasa's investors include Byron van Vugt, NZ Growth Capital Partners Aspire Fund, Saum Vahdat, Booster Innovation Fund, Bridgewest Group, Brisbane Angels, Cure Kids Ventures, Jacques Richter, Pacific Channel, Uniservices.
# High-Level Overview
Avasa is a New Zealand-based medical device company, not a general technology firm. Founded in 2018, the company develops solutions for reconstructive microsurgery, with its flagship product being the Avasa Coupler—a device that standardizes and simplifies the reconnection of micro-arteries during surgical procedures.[1] The company serves plastic surgeons and microsurgeons who perform reconstructive procedures, addressing a critical unmet need in a field where arterial reconnection has traditionally required manual hand-sewing under a microscope.[1]
The core problem Avasa solves is the complexity, time consumption, and variability of microvascular anastomosis (connecting small blood vessels). By automating and standardizing this process, Avasa aims to make microsurgery safer, faster, and more accessible globally.[1] The company is in advanced development stages, having recently secured pre-Series A funding and achieved design freeze on its Coupler, with pre-production units demonstrating 100% success in chronic animal studies.[1] Avasa is targeting FDA clearance and commercial market entry within 18 months of its funding announcement.
Avasa was founded in 2018 by Dr. Nandoun Abeysekera, a clinician-bioengineer who serves as CEO and Founder.[1] Abeysekera's background as a plastics resident provided direct clinical insight into the pain points of microsurgical practice, informing the development of the Coupler.[1] The company emerged from seven years of intensive research and development, during which the founding team validated market demand through interviews with over 100 microsurgeons—89% of whom expressed strong clinical demand for the solution.[1]
This human-centered approach to product development, grounded in Abeysekera's own surgical experience, represents a pivotal moment: the transition from identifying a problem to engineering a scalable solution. The recent recruitment of a senior commercial executive from Fisher & Paykel Healthcare signals the company's shift from R&D-focused operations toward go-to-market execution.[1]
Avasa operates within the medical device and surgical technology sector, riding the broader trend of automation and standardization in healthcare. The timing is particularly favorable: healthcare systems globally face surgeon shortages, rising procedural costs, and variability in surgical outcomes. By reducing the skill and time required for complex microsurgical procedures, Avasa addresses these systemic pressures.
The company also exemplifies the medtech innovation model emerging from smaller markets: New Zealand's healthcare ecosystem has produced several successful medical device companies, and Avasa benefits from this established infrastructure and expertise. Its focus on reconstructive microsurgery—a high-value, specialized field—positions it in a niche market with limited competition but significant clinical impact.
Avasa is at an inflection point. With design freeze achieved, animal study validation complete, and pre-Series A funding secured, the company is transitioning from development to regulatory and commercial execution. The next 18 months will be critical: FDA clearance timelines, initial market adoption among early-adopter surgeons, and proof of commercial viability will determine whether the Coupler becomes the new standard in microsurgery.
The broader opportunity is substantial—if successful, Avasa could reshape how microsurgical procedures are performed globally, improving outcomes while reducing surgeon burden. This positions the company not just as a device manufacturer, but as a potential category creator in surgical automation. The influx of commercial talent and investor backing suggests confidence in this vision, though execution risk remains inherent to medical device development and regulatory approval.